连续前房穿刺对玻璃体腔抗VEGF注射后持续眼压升高的影响
该回顾性病历回顾纳入17例患者23只眼,在接受中位26次抗VEGF玻璃体腔注射期间出现注射前眼压持续升高,随后每次注射后立即行前房穿刺至少连续3次。结果显示前房穿刺使注射前眼压从21.1 mmHg回落至基线16.00 mmHg,视盘杯盘比稳定,但多数眼仍需增加降眼压药物或额外治疗。
要点
- 连续前房穿刺可使抗VEGF注射后持续升高的注射前眼压回落至基线水平。
- 前房穿刺后视盘杯盘比保持稳定,最大值眼压从26.8 mmHg降至23.0 mmHg。
- 多数眼仍需增加局部降眼压药物,部分眼需激光或青光眼引流装置手术。
核心结论
- 连续前房穿刺可降低注射后即刻眼压,并配合标准青光眼治疗逆转注射前眼压升高、稳定视神经改变。
研究设计与样本
- 回顾性病历回顾,纳入17例患者23只眼,均接受贝伐珠单抗、雷珠单抗或阿柏西普玻璃体腔注射。
- 纳入标准为注射前眼压持续升高且至少连续3次注射后立即行前房穿刺。
- 比较抗VEGF治疗开始前后及前房穿刺引入前后的注射前眼压和杯盘比变化。
主要发现
- 患者接受中位26次玻璃体腔注射后,注射前眼压从16.3 mmHg升至21.1 mmHg(P=0.004)。
- 平均杯盘比从0.37增至0.47(P=0.0002)。
- 引入前房穿刺(中位12次)后,平均眼压回落至基线16.00 mmHg(P=0.002)。
- 平均杯盘比稳定于0.50(P=0.197),最大眼压从26.8 mmHg降至23.0 mmHg(P=0.05)。
- 19只眼(82.6%)研究期间需增加局部降眼压药物,13只眼(56.5%)在前房穿刺后仍需额外治疗,5只眼(38.5%)需激光或青光眼引流装置手术。
临床怎么用
- 对反复抗VEGF注射后出现注射前眼压持续升高的眼,可考虑连续前房穿刺以控制注射后即刻眼压。
- 前房穿刺应结合标准青光眼治疗,多数患者仍需降眼压药物或进一步手术干预。
局限性
- 回顾性设计,样本量小(17例23只眼),无对照组。
- 前房穿刺引入时间及次数不一,可能影响结果解释。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the effect of serial anterior chamber (AC) paracenteses in eyes with sustained elevations of intraocular pressure (IOP) in the setting of repeated intravitreal injections (IVI) of anti-vascular endothelial growth factor medications. METHODS: This is a retrospective records review of patients undergoing IVI of anti-vascular endothelial growth factor medication (bevacizumab, ranubizumab, or aflibercept), who demonstrated a sustained elevation of preinjection IOP and also received AC paracentesis immediately after IVI on at least three consecutive visits. Changes in preinjection IOP and cup-to-disk (C:D) ratio were compared before and after the initiation of IVI and before and after the introduction of AC paracenteses with each subsequent IVI. RESULTS: Twenty-three eyes of 17 patients receiving a median of 26 IVI experienced a rise in preinjection IOP from 16.3 mmHg to 21.1 mmHg (P = 0.004) and an increase in mean C:D ratio from 0.37 to 0.47 (P = 0.0002). After introduction of AC paracenteses (median of 12), mean IOP was returned to baseline 16.00 mmHg (P = 0.002), mean C:D ratio stabilized (0.50, P = 0.197), and maximum IOP decreased from 26.8 mmHg to 23.0 mmHg (P = 0.05). Nineteen (82.6%) eyes required an increase in topical glaucoma medications during the study period, and 13 (56.5%) still required additional therapies after initiation of AC paracenteses. Five eyes (38.5%) required laser or glaucoma drainage device procedures. CONCLUSION: Serial AC paracenteses reduced immediate postinjection IOP, and along with standard glaucoma care in most patients, reversed preinjection IOP elevation, and stabilized optic nerve changes associated with repeated intravitreal anti-vascular endothelial growth factor injections in a subset of patients with sustained elevation of preinjection IOP.
引用
- Sisk RA, Rusia D, Zamora BG, et al. EFFECT OF SERIAL ANTERIOR CHAMBER PARACENTESIS ON SUSTAINED INTRAOCULAR PRESSURE ELEVATION IN PATIENTS RECEIVING INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY. Retina. 2019. PMID: 30234855. doi:10.1097/IAE.0000000000002314
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。